OBJECTIVE: To estimate the prevalence of the hepatitis C virus (HCV) and HIV infection and associated risk behaviors among injection drug users (IDUs) in two northern Mexican cities. MATERIAL AND METHODS: Between February and April 2005, IDUs were recruited in Tijuana (N=222) and Ciudad Juarez (N=206) using respondent-driven sampling (RDS), a chain referral sampling approach. Interviewer-administered questionnaires assessed drug-using behaviors during the prior six months. Venous blood was collected for immunoassays to detect HIV and HCV antibodies. For HIV, Western blot or immunofluorescence assay was used for confirmatory testing. Final HCV antibody prevalence was estimated using RDS adjustments. RESULTS: Overall, HCV and HIV prevalence was 96.0% and 2.8%, respectively, and was similar in both cities. Most IDUs (87.5%) reported passing on their used injection equipment to others, and 85.9% had received used equipment from others. CONCLUSIONS: HIV prevalence was relatively high given the prevalence of HIV in the general population, and HCV prevalence was extremely high among IDUs in Tijuana and Ciudad Juarez. Frequent sharing practices indicate a high potential for continued transmission for both infections. HCV counseling and testing for IDUs in Mexico and interventions to reduce sharing of injection equipment are needed.
OBJECTIVE: To estimate the prevalence of the hepatitis C virus (HCV) and HIV infection and associated risk behaviors among injection drug users (IDUs) in two northern Mexican cities. MATERIAL AND METHODS: Between February and April 2005, IDUs were recruited in Tijuana (N=222) and Ciudad Juarez (N=206) using respondent-driven sampling (RDS), a chain referral sampling approach. Interviewer-administered questionnaires assessed drug-using behaviors during the prior six months. Venous blood was collected for immunoassays to detect HIV and HCV antibodies. For HIV, Western blot or immunofluorescence assay was used for confirmatory testing. Final HCV antibody prevalence was estimated using RDS adjustments. RESULTS: Overall, HCV and HIV prevalence was 96.0% and 2.8%, respectively, and was similar in both cities. Most IDUs (87.5%) reported passing on their used injection equipment to others, and 85.9% had received used equipment from others. CONCLUSIONS: HIV prevalence was relatively high given the prevalence of HIV in the general population, and HCV prevalence was extremely high among IDUs in Tijuana and Ciudad Juarez. Frequent sharing practices indicate a high potential for continued transmission for both infections. HCV counseling and testing for IDUs in Mexico and interventions to reduce sharing of injection equipment are needed.
Authors: S Koblavi-Dème; C Maurice; D Yavo; T S Sibailly; K N'guessan; Y Kamelan-Tano; S Z Wiktor; T H Roels; T Chorba; J N Nkengasong Journal: J Clin Microbiol Date: 2001-05 Impact factor: 5.948
Authors: Kachit Choopanya; Don C Des Jarlais; Suphak Vanichseni; Philip A Mock; Dwip Kitayaporn; Udomsak Sangkhum; Boonrawd Prasithiphol; Krit Hiranrus; Frits van Griensven; Jordan W Tappero; Timothy D Mastro Journal: J Acquir Immune Defic Syndr Date: 2003-05-01 Impact factor: 3.731
Authors: D C Des Jarlais; S R Friedman; D M Novick; J L Sotheran; P Thomas; S R Yancovitz; D Mildvan; J Weber; M J Kreek; R Maslansky Journal: JAMA Date: 1989-02-17 Impact factor: 56.272
Authors: H B de Carvalho; F Mesquita; E Massad; R C Bueno; G T Lopes; M A Ruiz; M N Burattini Journal: J Acquir Immune Defic Syndr Hum Retrovirol Date: 1996-05-01
Authors: Steffanie A Strathdee; Carlos Magis-Rodriguez; Vickie M Mays; Richard Jimenez; Thomas L Patterson Journal: Ann Epidemiol Date: 2012-06 Impact factor: 3.797
Authors: Laura B Moyer; Kimberley C Brouwer; Stephanie K Brodine; Rebeca Ramos; Remedios Lozada; Michelle Firestone Cruz; Carlos Magis-Rodriguez; Steffanie A Strathdee Journal: Drug Alcohol Rev Date: 2008-01
Authors: Steffanie A Strathdee; Remedios Lozada; Shirley J Semple; Prisci Orozovich; Minya Pu; Hugo Staines-Orozco; Miguel Fraga-Vallejo; Hortensia Amaro; Adela Delatorre; Carlos Magis-Rodríguez; Thomas L Patterson Journal: Sex Transm Dis Date: 2008-03 Impact factor: 2.830
Authors: Steffanie A Strathdee; Morgan M Philbin; Shirley J Semple; Minya Pu; Prisci Orozovich; Gustavo Martinez; Remedios Lozada; Miguel Fraga; Adela de la Torre; Hugo Staines; Carlos Magis-Rodríguez; Thomas L Patterson Journal: Drug Alcohol Depend Date: 2007-08-21 Impact factor: 4.492
Authors: Philip R Spradling; Jian Xing; Alba Phippard; Maureen Fonseca-Ford; Sonia Montiel; Norma Luna Guzmán; Roberto Vázquez Campuzano; Gilberto Vaughan; Guo-liang Xia; Jan Drobeniuc; Saleem Kamili; Ricardo Cortés-Alcalá; Stephen H Waterman Journal: J Immigr Minor Health Date: 2013-04
Authors: Angela R Bazzi; Jennifer L Syvertsen; María Luisa Rolón; Gustavo Martinez; Gudelia Rangel; Alicia Vera; Hortensia Amaro; Monica D Ulibarri; Daniel O Hernandez; Steffanie A Strathdee Journal: J Subst Abuse Treat Date: 2015-09-21
Authors: Robin A Pollini; Remedios Lozada; Manuel Gallardo; Perth Rosen; Alicia Vera; Armando Macias; Lawrence A Palinkas; Steffanie A Strathdee Journal: AIDS Behav Date: 2010-06
Authors: Richard S Garfein; Rafael Laniado-Laborin; Timothy C Rodwell; Remedios Lozada; Robert Deiss; Jose Luis Burgos; Jazmine Cuevas-Mota; Paris Cerecer; Kathleen Moser; Maria Luisa Volker; Steffanie A Strathdee Journal: Emerg Infect Dis Date: 2010-05 Impact factor: 6.883
Authors: R S Garfein; R Lozada; L Liu; R Laniado-Laborin; T C Rodwell; R Deiss; J Alvelais; A Catanzaro; P G Chiles; S A Strathdee Journal: Int J Tuberc Lung Dis Date: 2009-05 Impact factor: 2.373